Therefore, immune checkpoint blockades (ICIs) are monoclonal antibodies that enhance the anti-tumor activity of T cells by blocking the CTLA-4/B7 or PD-1/PD-L1 immune checkpoint pathways, thereby activating the immune system [20]. This evidence concerns the gene CD274 and neoplasm.